Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IPI-145, ABBV-954
duvelisib · 1 trial · 1 indication
The number of participants reporting treatment-emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| duvelisib | EXPERIMENTAL | Duvelisib will be administered orally as a fixed dose in 28-day cycles. |
| Name | Type | Description |
|---|---|---|
| duvelisib | DRUG | Duvelisib will be administered orally as a fixed dose in 28-day cycles. |
Inclusion Criteria: * Diagnosis of lymphoma (excluding lymphoblastic lymphoma) * Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease for which there is no established therapy * Eastern Cooperative Oncology Group (ECOG) performance status lower th...
Top 20 of 70 competitors
Duvelisib is being studied for the treatment of lymphoma. The clinical program described here focuses on Japanese subjects with relapsed or refractory lymphoma, a cancer of the lymphatic system. Duvelisib is an investigational small molecule and is not described as approved for this use.
Duvelisib targets PIK3CG and PIK3CD, two isoforms of phosphoinositide 3-kinase. It acts as an inhibitor of these targets. By inhibiting PIK3CG and PIK3CD, duvelisib interferes with signaling pathways involved in the growth and survival of lymphoma cells.
Duvelisib is being developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company associated with the clinical program for duvelisib in lymphoma.
Duvelisib is in Phase 1 clinical development for lymphoma. The program includes one completed Phase 1 trial. Duvelisib is investigational and is not described as approved.
Duvelisib has been evaluated in a Phase 1 trial, NCT02598570, titled "Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma." The trial enrolled 7 subjects in Japan and is completed. It was an uncontrolled study without randomization or blinding.